Join Growin Stock Community!

Cadrenal therapeutics, inc. common stockCVKD.US Overview

US StockHealthcare
(No presentation for CVKD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CVKD AI Insights

CVKD Overall Performance

CVKD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CVKD Recent Performance

0.59%

Cadrenal therapeutics, inc. common stock

0.05%

Avg of Sector

-0.31%

S&P500

CVKD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CVKD Key Information

CVKD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CVKD Profile

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Price of CVKD

CVKD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CVKD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.15
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
7.17
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.15
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
7.17
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CVKD's latest earnings report released?

    The most recent financial report for Cadrenal therapeutics, inc. common stock (CVKD) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CVKD's short-term business performance and financial health. For the latest updates on CVKD's earnings releases, visit this page regularly.

  • How much cash does CVKD have?

    At the end of the period, Cadrenal therapeutics, inc. common stock (CVKD) held Total Cash and Cash Equivalents of 3.86M, accounting for 0.94 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CVKD's EPS continuing to grow?

    According to the past four quarterly reports, Cadrenal therapeutics, inc. common stock (CVKD)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.31. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CVKD?

    Cadrenal therapeutics, inc. common stock (CVKD)'s Free Cash Flow (FCF) for the period is -2.36M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 7.17% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CVKD?

    The latest valuation data shows Cadrenal therapeutics, inc. common stock (CVKD) has a Price-To-Earnings (PE) ratio of -1.7 and a Price/Earnings-To-Growth (PEG) ratio of 0.09. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.